1
Country: USA | Funding: $3.9B
Moderna is a pioneer in developing a new class of drugs based on messenger RNA (mRNA). This new drug platform is based on the discovery that in-vitro engeneered and injected mRNA can direct the body's cellular machinery to produce virtually any protein of interest, from native proteins to antibodies and other entirely new protein constructs with therapeutic activity both inside and outside cells. In other words, mRNA can guide the body to produce its own drugs. Moderna used mRNA to create the first COVID-19 vaccine and is now applying this technology to create vaccines for infectious diseases (influenza, RSV, HSV, etc.), immuno-oncology (melanoma, lung cancer, liver cancer, etc.), rare diseases and autoimmune diseases.
Moderna is a pioneer in developing a new class of drugs based on messenger RNA (mRNA). This new drug platform is based on the discovery that in-vitro engeneered and injected mRNA can direct the body's cellular machinery to produce virtually any protein of interest, from native proteins to antibodies and other entirely new protein constructs with therapeutic activity both inside and outside cells. In other words, mRNA can guide the body to produce its own drugs. Moderna used mRNA to create the first COVID-19 vaccine and is now applying this technology to create vaccines for infectious diseases (influenza, RSV, HSV, etc.), immuno-oncology (melanoma, lung cancer, liver cancer, etc.), rare diseases and autoimmune diseases.
2
Country: France | Funding: $1.1B
Valneva is a pharmaceutical company focused on the prevention of infectious diseases with significant unmet medical need.
Valneva is a pharmaceutical company focused on the prevention of infectious diseases with significant unmet medical need.
3
Country: USA | Funding: $765M
VBI Vaccines is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. VBI’s eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines that closely mimic the target virus.
VBI Vaccines is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. VBI’s eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines that closely mimic the target virus.
4
Country: USA | Funding: $377.5M
Affinivax is a biotechnology company developing technology to provide broad protection against diseases affecting children.
Affinivax is a biotechnology company developing technology to provide broad protection against diseases affecting children.
5
Country: UK | Funding: $240M
Barinthus Biotherapeutics is creating novel vaccines that elicit strong responses from helper and cytotoxic T-cells.
Barinthus Biotherapeutics is creating novel vaccines that elicit strong responses from helper and cytotoxic T-cells.
6
Country: Denmark | Funding: $215.5M
Minervax is a biotechnology company developing a novel vaccine against Group B Streptococcus.
Minervax is a biotechnology company developing a novel vaccine against Group B Streptococcus.
7
Country: USA | Funding: $196M
Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines for infectious diseases.
Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines for infectious diseases.
8
Country: Australia | Funding: $162.4M
Vaxxas is pioneering a next-generation vaccine delivery platform that enables robust immune system activation by targeting vaccine components to the abundant immunological cells immediately below the surface of the skin. Vaxxas' proprietary Nanopatch technology aims to provide an optimized, differentiated needle-free vaccine delivery solution that safely and cost effectively amplifies vaccine efficacy.
Vaxxas is pioneering a next-generation vaccine delivery platform that enables robust immune system activation by targeting vaccine components to the abundant immunological cells immediately below the surface of the skin. Vaxxas' proprietary Nanopatch technology aims to provide an optimized, differentiated needle-free vaccine delivery solution that safely and cost effectively amplifies vaccine efficacy.
9
Country: USA | Funding: $100M
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization dedicated to accelerating the product development timeline for diseases that disproportionately affect the world’s poorest populations, starting with malaria, tuberculosis, and diarrheal diseases—diseases that combined cause five deaths every minute.*
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization dedicated to accelerating the product development timeline for diseases that disproportionately affect the world’s poorest populations, starting with malaria, tuberculosis, and diarrheal diseases—diseases that combined cause five deaths every minute.*
10
Country: UK | Funding: $100M
Vicebio is committed to employing the Molecular Clamp Technology to create vaccines against next-generation respiratory viruses.
Vicebio is committed to employing the Molecular Clamp Technology to create vaccines against next-generation respiratory viruses.
11
Country: USA | Funding: $73M
kernal biologics is mRNA vaccine and therapeutics company. It develops onco-selective mRNA immunotherapy
kernal biologics is mRNA vaccine and therapeutics company. It develops onco-selective mRNA immunotherapy
12
Country: France | Funding: $69.6M
Osivax is a clinical stage biotechnology company developing a pipeline of vaccines and immunotherapies.
Osivax is a clinical stage biotechnology company developing a pipeline of vaccines and immunotherapies.
13
Country: USA | Funding: $65.6M
Codagenix employs a proprietary technology platform for the construction of live attenuated viral vaccines for flu and other targets.
Codagenix employs a proprietary technology platform for the construction of live attenuated viral vaccines for flu and other targets.
14
Country: UK | Funding: $65.4M
Oxitec is a pioneer in controlling insects that spread disease and damage crops. Through world class science we have developed an innovative new solution to controlling harmful insects pests.
Oxitec is a pioneer in controlling insects that spread disease and damage crops. Through world class science we have developed an innovative new solution to controlling harmful insects pests.
15
Country: USA | Funding: $11.4M
CaroGen Corporation is an immunotherapy company employing a virus-like vesicle (VLV) platform technology. CaroGen develops vaccine candidates targeting hepatitis B and C, and other viral agents.
CaroGen Corporation is an immunotherapy company employing a virus-like vesicle (VLV) platform technology. CaroGen develops vaccine candidates targeting hepatitis B and C, and other viral agents.
16
Country: Australia
Vaxine is focused on development of innovative vaccine technologies. Vaxine’s human candidates include vaccines against seasonal and pandemic influenza, hepatitis B, Japanese encephalitis, West Nile Virus, malaria, rabies, and allergy.
Vaxine is focused on development of innovative vaccine technologies. Vaxine’s human candidates include vaccines against seasonal and pandemic influenza, hepatitis B, Japanese encephalitis, West Nile Virus, malaria, rabies, and allergy.
